Subject:ERWINAZE® Batch 198K Notice of *New* Special Handling Instructions
Use a 0.2-micron, low protein binding, in-line filter for IV administration of
ERWINAZE® (asparaginase Erwinia chrysanthemi) from BATCH 198K.
Dear Health Care Provider:
The purpose of this letter is to alert you that ERWINAZE (asparaginase Erwinia chrysanthemi) from Batch 198K may be administered either intramuscularly (IM) or intravenously (IV) according to the instructions outlined in this letter that are intended to prevent the administration of particulate matter that may be found in some of the product.
During routine visual inspections of ERWINAZE Batch 198K, particulate matter was observed in some vials. These affected vials were set aside and not released. However, some of the released vials may still contain particulate matter, which, if present in reconstituted ERWINAZE, may pose a safety risk to patients.
If you observe particulate matter in the vial either before or after reconstitution, you should quarantine the vial and not administer it to the patient. If no particulates are observed, you should use a 5-micron filter needle to withdraw the reconstituted ERWINAZE product from the vials. Additionally, for IV administration, use a 0.2-micron, low protein binding, in-line filter attached to the primary IV tubing when administering the final IV mixture to patient. Because of the critical necessity of this drug, Jazz Pharmaceuticals is asking health care providers to take these necessary steps for patient safety.
In order to minimize the potential risk of adverse events, health care providers should use a standard 5‐micron filter needle to withdraw the reconstituted ERWINAZE product from the vial, and then discard the filter needle and replace it with an appropriate needle prior to IM administration or transfer to an IV infusion bag.
If the health care provider decides to administer ERWINAZE intravenously, health care providers should use an additional 0.2‐micron, low protein binding, in-line filter when administering the final IV admixture to patient. Testing performed with a Baxter IV tubing extension set with 0.2 micron filter (Baxter Catalog ID: 2C8671) demonstrated no impact to Erwinaze product quality.
Please follow the instructions below prior to withdrawing the reconstituted ERWINAZE product from the vials and administering it to patients.
Prior to reconstitution, carefully inspect each vial. If you observe particulate matter anywhere in the vial, quarantine the vial. If you do not observe particulate matter in the vials, reconstitute the product as set forth below.
Follow all recommended steps for reconstitution of ERWINAZE in accordance with the Prescribing Information.
Carefully inspect reconstituted product. In the event that you discover visible
particulate matter in the reconstituted product, do not administer to the patient and quarantine the vial.
If no visible particulate matter is seen in the reconstituted product, use a standard 5‐micron filter needle to withdraw the reconstituted product from the vial. See filter needle manufacturer’s instructions or usage guidelines for proper use of filter needle.
Discard the filter needle and replace with an appropriate needle prior to patient administration or transfer to an IV infusion bag.
NOTE: ERWINAZE may be administered by either IM injection or IV infusion. IV administration requires the additional use of a 0.2-micron, low protein binding, in-line filter attached to the primary IV tubing.
If you see particulate matter anywhere in the vial, do not administer to the patient and quarantine the vial. Contact Jazz Pharmaceuticals Medical Information at 1‐800‐520‐5568 to report the issue and to discuss appropriate resolution.
The following label, attached to the carton, can identify vials from ERWINAZE Batch 198K:
REQUIRES 5-MICRON FILTER NEEDLE
IV ADMINISTRATION REQUIRES THE ADDITIONAL USE OF A 0.2-MICRON, LOW PROTEIN BINDING, IN-LINE FILTER
SEE INCLUDED IMPORTANT INFORMATION LETTER
Vials from ERWINAZE Batch 198K can also be identified by numbering on the individual vial labels. Vials from the affected batch will have one of the following lot numbers: 198K119, 198K219, 198K319, 198K419 or 198K519.
Please ensure that your staff and any provider in your institution who may be involved in the reconstitution and administration of ERWINAZE receives a copy of this letter and specifically reviews the Updated Instructions for Preparation appended to this letter. Please pay special attention to the updates in steps #1- #7 that include observation of particulate matter and the use of a 5‐micron filter needle to withdraw the reconstituted ERWINAZE, and additional requirements for IV use.
Please see accompanying Full Prescribing Information for ERWINAZE.
Regular mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.
Noam Frey, MD MBA
Vice President, Pharmacovigilance and Medical Affairs
Jazz Pharmaceuticals, Inc.
Updated Instructions for Preparation: ERWINAZE Batch 198K Vial
Preparation and Handling Instructions
Carefully inspect each vial. If you observe particulate matter, quarantine the vial. If you do not observe particulate matter, reconstitute the product as follows.
Reconstitute the contents of each vial by slowly injecting 1 or 2 mL of preservative free sterile sodium chloride (0.9%) injection (USP) against the inner vial wall.
Do not forcefully inject solution for reconstitution directly onto or into the powder. When reconstituted with 1 mL the resultant concentration is 10,000 International Units per mL. When reconstituted with 2 mL the resultant concentration is 5,000 International Units per mL.
Dissolve contents by gentle mixing or swirling. Do not shake or invert vial.
When reconstituted, ERWINAZE should be a clear, colorless solution. Inspect the solution after reconstitution for any visible particles or protein aggregates, if you observe particulate matter in the reconstituted product, quarantine the vial.
Calculate the dose needed and the volume needed to obtain the calculated dose.
Withdraw the volume containing the calculated dose from the vial using a 5-micron filter needle (according to the filter needle manufacturer’s instructions) into a polypropylene syringe within 15 minutes of reconstitution. Discard the filter needle and replace with an appropriate needle prior to administration or transfer of the reconstituted product to an IV infusion bag. For intravenous use, slowly inject the reconstituted ERWINAZE into an IV infusion bag containing 100 mL of normal saline acclimatized to room temperature. Do not shake or squeeze the IV bag.
If a partial vial is used, do not save or reuse the unused drug for later administration. Discard unused portions.
Do not freeze or refrigerate reconstituted solution and administer within 4 hours or discard [see Prescribing Information - How Supplied/Storage and Handling (16)].
If you see particulate matter anywhere other on than the underside of the stopper (pre‐ or post‐ reconstitution), do not administer to the patient and quarantine the vial. Contact Jazz Pharmaceuticals Medical Information at 1‐800‐520‐5568 to report the issue and to discuss appropriate resolution.
Administration Instructions for ERWINAZE Batch 198K
ERWINAZE solution may be administered by either intramuscular injection or intravenous infusion
For intramuscular use, limit the volume of reconstituted ERWINAZE at a single injection site to 2 mL; if reconstituted dose to be administered is greater than 2 mL, use multiple injection sites.
For Intravenous use, use an additional 0.2‐micron, low protein binding, in-line filter when administering the final IV admixture to patient. Infuse ERWINAZE in 100 mL of normal saline over 1 to 2 hours. Do not infuse other intravenous drugs through the same intravenous line while infusing.
If you have any questions, please call Jazz Customer Support at 650-496-3777
YOU ARE NOW LEAVING ERWINAZE.COM
Click “OK” to continue or “Cancel” to return to ERWINAZE.com.